1	Use of rapid molecular tuberculosis diagnostics across Brazil's incarcerated population
2	
3	Elinor B. Fajer ¹ , Fernanda Dockhorn Costa ² , Daniele Maria Pelissari ² , Fredi Alexander Diaz
4	Quijano ³ , Artemir Coelho de Brito ² , Eunice Atsuko Totumi Cunha ⁴ , Julio Croda ^{5,6,7} , Jason R.
5	Andrews ¹ , Katharine S. Walter ¹
6	
7	1. Stanford University School of Medicine, Stanford, CA, United States
8	2. National Tuberculosis Control Program, Brasília, DF, Brazil
9	3. Department of Epidemiology, School of Public Health, University of São Paulo, São Paulo,
10	SP, Brazil
11	4. Central Laboratory of Public Health, Campo Grande, Brazil
12	5. Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
13	6. Oswaldo Cruz Foundation, Campo Grande, Brazil
14	7. Yale School of Public Health, New Haven, CT, United States
15	
16	Running Head: TB diagnostic use among prison populations
17	
18	Article Word Count: 2433
19	References: 30
20	Tables: 2
21	Figures: 4
22	
23	Keywords: tuberculosis; prisons; diagnostic gap; Xpert MTB/RIF
24	
25	Correspondence:
26	Elinor B. Fajer
27	Stanford University
28	450 Serra Mall
29	Stanford, CA, USA, 94305
30	Email: efajer@stanford.edu
31	

32 Abstract (200 words)

- 33 Background: Incarcerated individuals in Brazil are at high-risk of tuberculosis (TB), but their
- 34 access to World Health Organization recommended diagnostics is poorly understood.
- 35 Methods: We conducted a retrospective cross-sectional study of newly diagnosed TB cases in
- 36 Brazil's notifiable disease registry, which includes information on diagnostic tests performed,
- 37 from January 2015 through December 2018. We quantified reported use of TB diagnostics across
- 38 incarcerated and non-incarcerated populations and tested for municipality-level factors
- 39 associated with diagnostic usage among the incarcerated population with generalized linear
- 40 regression.
- 41 **Results**: Between 2015 and 2018, 258,014 individuals were newly diagnosed with TB, including
- 42 27,400 (10.6%) incarcerated individuals. Among these, 27.5% had an Xpert MTB/RIF test
- 43 reported; 71.5% had sputum smear; 34.1% had culture; 70.9% had chest radiography. Xpert
- 44 MTB/RIF use was greater among incarcerated than non-incarcerated individuals (36.2% vs
- 45 26.5%, p<0.001). However, we found spatial heterogeneity in state-level use of both Xpert
- 46 MTB/RIF (range: 4.7-72.4% cases diagnosed) and chest radiography (range: 11.7-88.4%) in
- 47 prisons. We identified seven municipalities with large incarcerated populations (>5000) with
- 48 rates of Xpert MTB/RIF usage below the national average in incarcerated individuals.
- 49 **Conclusion**: Prioritizing expansion of rapid molecular diagnostics in prisons, particularly in
- 50 regions with limited current usage of molecular diagnostics, will be an essential component of
- 51 TB control.
- 52
- 53

54 INTRODUCTION

55

Tuberculosis (TB) is one of the leading causes of death by infectious disease worldwide¹.
However, there remains a large population of undiagnosed TB cases, which the COVID-19
pandemic has further expanded¹. In 2020, of the estimated 9.9 million globally incident TB
cases, only 5.8 million cases were reported¹. Reducing this diagnostic gap through early
diagnosis of disease and rapid detection of drug resistance is critical for both managing
individual outcomes and for preventing onwards transmission of TB¹⁻³.

62 As part of the End TB Strategy, the World Health Organization (WHO) recommends that 63 all individuals with symptoms of TB should have access to WHO-endorsed molecular rapid 64 diagnostic tests⁴. Rapid molecular diagnostic tests such as Xpert MTB/RIF have high sensitivity 65 (89%) and specificity (99%) in detecting *M. tuberculosis* when compared to a microbiological reference standard and a low limit of detection^{5,6}, enabling detection of M. tuberculosis in 66 67 paucibacillary samples. Further, automated molecular diagnostics like Xpert MTB/RIF do not 68 require biosafety level three facilities, extensive laboratory capacity, or long follow-up periods, 69 as do many other diagnostics. However, in many high-incidence countries, sputum smear 70 microscopy remains the most used diagnostic test, and culture remains the gold standard for TB 71 positivity.

72 Expanding access to rapid molecular TB diagnostics is an urgent priority for vulnerable 73 populations such as incarcerated individuals, who globally have a TB incidence ten times that of the general population⁷. In the Americas, TB notifications are increasingly concentrated within 74 prisons^{8,9}, including in Brazil, where 12.2% of the country's notified TB cases occurred among 75 incarcerated individuals in 2019¹¹. The conditions of detention put individuals at high risk of TB 76 77 infection and often reduce their contact with healthcare systems, resulting in a lower probability of early diagnosis and treatment^{9,12}. Higher TB levels across incarcerated populations not only 78 79 affect these groups of people directly, but also have impacts at the population level due to amplifying factors such as spillover $^{13-15}$. 80

Early diagnosis and treatment is critical for reducing the burden of TB in prisons, and the speed, accessibility, and cost effectiveness of Xpert MTB/RIF makes it especially suitable in prison settings¹⁶. Modeling studies have found that active screenings with Xpert MTB/RIF can significantly reduce the burden of TB among incarcerated populations^{13,17–19}. While the Brazil

85 National Tuberculosis Program recently endorsed the use of Xpert MTB/RIF, the usage of rapid 86 molecular diagnostics in prisons has not yet been explored. Additionally, as studies have supported chest radiography use for mass screenings in prison settings¹⁷, the usage of this 87 diagnostic across Brazil's incarcerated population is also of interest. 88 89 Here, we analyzed Brazil's national notifiable disease registry to quantify the use of 90 Xpert MTB/RIF and chest radiography across Brazil's incarcerated population and to identify 91 critical gaps in the usage of recommended diagnostics. 92 93 **METHODS** 94 95 Study design and data sources 96 97 We conducted a retrospective cohort study of newly diagnosed tuberculosis cases 98 reported to Brazil's national notifiable disease system, Sistema de Informação de Agravos de 99 Notificação (SINAN), from January 2015 through December 2018. In Brazil, individual tuberculosis diagnoses are compulsorily reported in SINAN²⁰. SINAN includes patient clinical 100 101 and sociodemographic information, incarceration status at the time of TB notification, TB 102 diagnostic test results, and TB treatment outcomes. We restricted the study period to between 103 2015 and 2018 as Xpert MTB/RIF implementation began in late 2014, and data for years 104 following 2018 were incomplete at the time of the study. We excluded cases with unknown 105 incarceration status or of patients below 18 years of age, as they make up a small proportion of 106 the incarcerated population in Brazil. Patients may receive more than one diagnostic test to confirm their TB diagnosis. SINAN 107 108 reports diagnostic results by testing modality, including Xpert MTB/RIF, chest radiography, sputum smear, and culture. Xpert MTB/RIF test outcomes are reported as M. tuberculosis 109

110 detected, sensitive to Rifampicin; *M. tuberculosis* detected, resistant to Rifampicin; *M.*

111 *tuberculosis* not detected; inconclusive test; or not performed. Xpert MTB/RIF G4 was primarily

used during our study period, though Brazil introduced Xpert MTB/RIF Ultra across the

113 country's laboratory network in 2019. Chest radiography test outcomes are reported as suspect,

normal, other pathology, or not performed; sputum smear outcomes are reported as positive,

negative, not performed, or not applicable; and culture outcomes are reported as positive,

116 negative, in-progress, or not performed. For each individual diagnostic test, we classified 117 individuals with positive, negative, or in-progress reported results as having received that test 118 (test usage), and individuals with tests marked not performed or missing information as having 119 not received that diagnostic test (no test usage). At the municipality level, we defined test use as 120 the proportion of cases diagnosed with each respective diagnostic tool. 121 In addition to the individual level variables extracted from SINAN, we collected 122 municipality-level covariates, including average per capita household income and GINI coefficient, from the Human Development Atlas²¹. The Human Development Atlas collects data 123 124 each decade; therefore, we used data from the most recent report (2010). We obtained incarcerated population size by municipality from Brazil's National Prison Information Survey²² 125 126 and data for total municipality population density from the Brazilian Institute of Geography and Statistics²³. 127 128 Statistical Analysis

- 129
- 130

131 Data analysis was conducted using R (version 3.6.3) and R Studio (version 1.3.1093). We 132 first compared the proportions of patients diagnosed with Xpert MTB/RIF, chest radiography, 133 sputum smear, and culture between incarcerated and non-incarcerated populations with two-134 proportion z-tests. A multiple samples proportions test was performed to assess the increasing 135 trend in Xpert MTB/RIF use over the study period.

136 We calculated use of the four testing modalities at state and municipality levels based on 137 individual-level data from SINAN and the location of patients' diagnoses. Chi-square tests for 138 equality of proportions were run to assess the significance of state-level diagnostic use heterogeneity. An 'empty' multilevel regression²⁴ was run with state or municipality random 139 140 effects respectively and no other predictor variables. These models were used to estimate the 141 intraclass correlation coefficients (ICC) for municipality and state-level clustering, a measure of 142 the proportion of total variability as determined by cluster membership.

143 We used mixed effects binomial regression to identify covariates associated with use of Xpert MTB/RIF and chest radiography among the incarcerated population. We included 144 145 municipality population density, GINI coefficient, incarcerated population size, average per 146 capita household income, and year (2015 through 2018) as fixed effects, and municipality of TB

147 diagnosis as a random effect. The population density, incarcerated population size, and average 148 per capita household income variables were on a log scale. The GINI coefficient was rescaled by 149 a factor of ten for to optimize model fitting. 150 We investigated gaps in diagnostic use for all Brazil municipalities with incarcerated 151 populations of at least 5000 individuals and with at least 5 TB cases from 2015 through 2018. 152 153 **Ethics Statement** 154 155 This study was approved by the Institutional Review Board at Stanford University (Protocol 156 #50466). 157 158 159 RESULTS 160 161 In Brazil between 2015 and 2018, there were 284,415 newly diagnosed TB cases reported to Brazil's Notifiable Diseases Information System (SINAN), of which 258,014 were among 162 163 patients over 18 years of age and with information on incarceration status. Of these notified 164 cases, 10.6% (27,400 of 258,014 cases) occurred among incarcerated individuals and 89.4% 165 (230,614 of 258,014) were among the general population. We found overall Xpert MTB/RIF use of 27.5% (70,988 of 258,014), chest radiography use of 70.9% (183,058 of 258,014), sputum 166 167 smear use of 71.5% (184,509 of 258,014), and culture use of 34.1% (87,905 of 258,014), with 168 significant overlap in populations receiving different diagnostic tests (Fig. 1). TB patients 169 received a mean of 2.04 diagnostic tests, with the greatest overlap of 27.4% of patients receiving 170 both chest radiography and sputum smear. 171 Between 2015 and 2018, use of Xpert MTB/RIF and chest radiography diagnostic testing 172 differed significantly between Brazil's incarcerated and non-incarcerated populations (Fig. 2). 173 Use of Xpert MTB/RIF for incarcerated individuals was greater than that for non-incarcerated 174 individuals (36.2% vs 26.5%, p-value<0.001 each year and overall). Xpert MTB/RIF use in 175 prison settings increased over the four years (p-value<0.001 for a positive linear trend in Xpert 176 MTB/RIF use). Chest radiography use was consistently lower for incarcerated individuals than 177 for non-incarcerated individuals (41.6% vs 74.4%, p-value<0.001 each year and overall).

Across Brazil's 26 states and one federal district, we found significant heterogeneity in usage in prisons for both Xpert MTB/RIF (X-squared=2717.3, df=26, p<0.001) and chest radiography (X-squared=9039.7, df=26, p<0.001) (Fig. 3). Diagnosis with Xpert MTB/RIF ranged from 4.7% and 4.9% in Pará and Mato Grosso, to 64.5% and 72.4% in Goiás and Amapá, respectively. Similarly, diagnosis with chest radiography ranged from 11.7% and 18.9% in São Paulo and Amapá, to 84.5% and 88.4% in Rio De Janeiro and Espírito Santo, respectively.

184 Brazil is further divided from the state level into 5,570 municipalities, of which 1,514 185 contain at least one prison, and 1,235 had at least one TB case from its incarcerated population 186 reported to SINAN between 2015 to 2018. Primary healthcare in Brazil, including healthcare within prisons, is provided by municipalities²⁵. We found that 21.3% and 52.1% of variation in 187 188 Xpert MTB/RIF use, as measured by intraclass correlation coefficients, can be attributed to a patient's state and municipality, respectively (Fig. 3c). Similarly, 22.8% and 54.9% of variation 189 190 in chest radiography use among incarcerated populations can be attributed to a patient's state and 191 municipality, respectively.

192 To identify other potential predictors of diagnostic use among the incarcerated 193 population, we fit binomial regression models for both diagnostics (Table 1). We found that 194 Xpert MTB/RIF use was greater in 2017 (OR:1.55, CI:1.42-1.69) and 2018 (OR:2.23, CI:2.03-195 2.44, p<0.001) compared to 2015. A greater municipality incarcerated population size was 196 associated with greater use of Xpert MTB/RIF (OR:1.76, CI:1.49-2.08, p<0.001), though 197 average per capita income, GINI coefficient, and population density were not significantly 198 correlated with Xpert MTB/RIF use. Additionally, we found that GINI coefficient and per capita 199 income were significantly positively associated with chest radiography use, while incarcerated 200 population size was negatively associated with chest radiography use.

To identify specific gaps in Xpert MTB/RIF and chest radiography usage across Brazil's incarcerated population, we further examined municipalities with incarcerated populations of at least 5000 individuals and with at least 5 diagnosed TB cases between 2015-2018 (Fig. 4, Table 204 2). Of these 26 municipalities, seven reported that less than the national average of 36.2% of incarcerated patients were diagnosed with Xpert MTB/RIF, and 18 reported that less than the national average of 41.6% of incarcerated patients diagnosed were with chest radiography.

207

208 **DISCUSSION**

209

210 We found that the use of TB diagnostic tests differs significantly between the 211 incarcerated and general populations in Brazil. The use of Xpert MTB/RIF was greater among 212 the incarcerated population and expanded in 2017 and 2018 compared to 2015, as expected with 213 the gradual implementation of this test across prisons. Further, we found that diagnosis with 214 Xpert MTB/RIF and chest radiography is largely determined by a patient's state and municipality 215 at time of diagnosis, reflecting the varying TB programs and control efforts organized by 216 Brazil's municipalities. Finally, we identified several gaps in which municipalities with large 217 prison populations had very limited use of Xpert MTB/RIF and/or chest radiography.

218 As a significant and increasing proportion of TB notifications in Brazil occur among the incarcerated population⁹, and as prisons can amplify community TB epidemics^{13–15}, targeting 219 220 prisons for TB control efforts can substantially impact Brazil's overall TB incidence. Given the 221 high accuracy of Xpert MTB/RIF in diagnosing TB and its effectiveness within prison settings^{6,16,26,27}, ensuring equitable access to this diagnostic across Brazil's incarcerated 222 223 population is critical. Our findings suggest that efforts to expand Xpert MTB/RIF availability in 224 prisons have been effective, as a greater proportion of incarcerated versus non-incarcerated 225 individuals were diagnosed with this test, and as the proportion diagnosed increased through the 226 study period. Yet our observation of significant spatial heterogeneity in Xpert MTB/RIF use 227 across Brazil's prisons indicates that a large population in Brazil may not currently have access to 228 this tool based on where they live. Thus, targeting the specific municipalities identified as having 229 large incarcerated populations and limited Xpert MTB/RIF use should be a focus of continued 230 Xpert MTB/RIF expansion and overall TB control efforts as addressing issues in these settings 231 could help to further limit TB incidence in and beyond prison settings.

232 Reducing the TB diagnostic gap remains a global challenge, and efforts to expand access 233 to Xpert MTB/RIF testing in prisons and across healthcare systems globally will be critical to achieve the WHO End TB Strategy of an 80% decrease in new cases by 2030⁴. Some countries 234 235 have reported rapid expansion of Xpert MTB/RIF. For example, in Uzbekistan, Xpert MTB/RIF coverage increased from 24% in 2018 to 46% in 2019²⁸, and in El Salvador, the use of Xpert 236 237 MTB/RIF testing as part of a package of TB diagnostic interventions tripled incarcerated TB notifications in five years²⁹. However, barriers to equitable diagnostic access remain, such as 238 diagnostic machine service coordination issues³⁰, and further research will be necessary to 239

identify diagnostic gaps and policy solutions. Our findings of significant spatial heterogeneity in
Xpert MTB/RIF usage across Brazil and by incarceration status highlight the importance of
understanding diagnostic availability for other national TB control programs.

243 There are several limitations to this study. First, availability of specific diagnostic tests 244 across Brazil's diagnostic facilities is not centrally reported, and individual access to diagnostic 245 tests cannot be ascertained from SINAN. We investigated the usage of different diagnostics 246 among confirmed cases, which may reflect availability of diagnostics in a particular setting, 247 functionality, and selection by healthcare providers. However, we were unable to investigate 248 how widely Xpert MTB/RIF is used among all individuals with suspected TB, and hence cannot 249 report usage for individuals who did not actually receive a confirmed diagnosis. Another 250 limitation was the use of 2010 socioeconomic indicators in the binomial regression. Though 251 these values have been improving over time, the 2015 economic crisis could have variably 252 influenced socioeconomic factors across municipalities; as a census has not been conducted 253 since, the 2010 data still provide a strong estimate. Third, we excluded cases where the 254 incarceration status was not reported. This represents under 3.2% of total cases (9,086 of 255 284,415), so we have confidence that excluding diagnostic usage data for this population does 256 not significantly impact our results. Finally, our study focuses on years preceding the COVID-19 257 pandemic. Understanding the effect of COVID-19 on widening TB diagnostic gaps within and 258 outside prisons is critical for TB control programs¹.

Ultimately, to achieve the WHO End TB goals, targeted expansion of rapid molecular diagnostics for incarcerated populations and regions with limited diagnostic usage will be essential and could reduce significant diagnostic gaps.

262

Funding: National Institutes of Health grant R01 AI130058 (JRA) and R01 AI149620 (JRA andJC).

EBF, KSW, JRA, and JC conceived of the study. EBF analyzed data and made data

visualizations. KSW and JC acquired data. All authors contributed to paper revisions andapproved of the final version.

- 268
- 269
- 270

271 **REFERENCES**

- 272
- Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021. Licence:
 CC BY-NC-SA 3.0 IGO.
- 275 2. Impact of the COVID-19 pandemic on TB detection and mortality in 2020. Accessed
- August 12, 2021. https://www.who.int/publications/m/item/impact-of-the-covid-19-
- 277 pandemic-on-tb-detection-and-mortality-in-2020
- 278 3. Pai M. Diagnostics for tuberculosis: what test developers want to know.
- 279 *http://dx.doi.org/101586/erm1316*. 2014;13(4):311-314. doi:10.1586/ERM.13.16
- WHO operational handbook on tuberculosis. Module 3: Diagnosis Rapid diagnostics for
 tuberculosis detection 2021 update. Accessed August 12, 2021.
- 282 https://www.who.int/publications/i/item/9789240030589
- 283 5. Marlowe EM, et al. Notes: Evaluation of the Cepheid Xpert MTB/RIF Assay for Direct
- Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens. *J Clin Microbiol.* 2011;49(4):1621. doi:10.1128/JCM.02214-10
- Steingart KR, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin
 resistance in adults. *Cochrane Database Syst Rev.* 2013;18(1):77-78.
- 288 doi:10.1002/14651858.CD009593.PUB2
- 289 7. Cords O, et al. Incidence and prevalence of tuberculosis in incarcerated populations: a
 290 systematic review and meta-analysis. *Lancet Public Heal*. 2021;6(5). doi:10.1016/S2468291 2667(21)00025-6
- 8. Sequera VG, et al. Increased incarceration rates drive growing tuberculosis burden in
 prisons and jeopardize overall tuberculosis control in Paraguay. *Sci Reports 2020 101*.
- 294 2020;10(1):1-7. doi:10.1038/s41598-020-77504-1
- Walter KS, et al. The escalating tuberculosis crisis in central and South American prisons. *Lancet*. 2021;397(10284):1591-1596. doi:10.1016/S0140-6736(20)32578-2
- Pelissari DM, Diaz-Quijano FA. Impact of incarceration on tuberculosis incidence and its
 interaction with income distribution inequality in Brazil. *Trans R Soc Trop Med Hyg*.
- 299 2020;114(1):23-30. doi:10.1093/TRSTMH/TRZ088
- TabNet Win32 3.0: TUBERCULOSE Casos confirmados notificados no Sistema de
 Informação de Agravos de Notificação Brasil. Accessed October 3, 2021.

302		http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinannet/cnv/tubercbr.def
303	12.	Reyes K, Amores JC. Barriers of Early TB Diagnosis among the Poor in Highly
304		Urbanized Areas in the Philippines. Published online 2014. Accessed July 19, 2021.
305		https://www.econstor.eu/handle/10419/126984
306	13.	Mabud TS, et al. Evaluating strategies for control of tuberculosis in prisons and
307		prevention of spillover into communities: An observational and modeling study from
308		Brazil. PLoS Med. 2019;16(1). doi:10.1371/JOURNAL.PMED.1002737
309	14.	Walter KS, et al. Genomic evidence for prisons as amplifiers of community tuberculosis
310		epidemics. medRxiv. Published online June 24, 2021:2021.06.22.21259360.
311		doi:10.1101/2021.06.22.21259360
312	15.	Baussano I, et al. Tuberculosis Incidence in Prisons: A Systematic Review. PLOS Med.
313		2010;7(12):e1000381. doi:10.1371/JOURNAL.PMED.1000381
314	16.	Dara M, et al. Tuberculosis control in prisons: current situation and research gaps. Int J
315		Infect Dis. 2015;32:111-117. doi:10.1016/J.IJID.2014.12.029
316	17.	Santos A da S, et al. Yield, Efficiency, and Costs of Mass Screening Algorithms for
317		Tuberculosis in Brazilian Prisons. Clin Infect Dis. 2021;72(5):771-777.
318		doi:10.1093/CID/CIAA135
319	18.	Pelissari DM, et al. Prevalence and screening of active tuberculosis in a prison in the
320		South of Brazil. Int J Tuberc Lung Dis. 2018;22(10):1166-1171.
321		doi:10.5588/IJTLD.17.0526
322	19.	Fournet N, et al. Development and evaluation of tuberculosis screening scores in Brazilian
323		prisons. Public Health. 2006;120(10):976-983. doi:10.1016/J.PUHE.2006.06.004
324	20.	Brasil Ministério da Saúde. Manual de Recomendações para o Controle da Tuberculose no
325		Brasil. Accessed July 19, 2021. www.saude.gov.br/
326	21.	Atlas Brasil. Accessed July 19, 2021. http://www.atlasbrasil.org.br/
327	22.	Infopen - National Prison Information Survey - Datasets - Ministry of Justice and Public
328		Security. Accessed July 19, 2021. http://dados.mj.gov.br/dataset/infopen-levantamento-
329		nacional-de-informacoes-penitenciarias
330	23.	Population IBGE. Accessed July 19, 2021.
331		https://www.ibge.gov.br/en/statistics/social/population.html
332	24.	Sommet N, Morselli D. Keep Calm and Learn Multilevel Logistic Modeling: A Simplified

- 333 Three-Step Procedure Using Stata, R, Mplus, and SPSS. *Int Rev Soc Psychol*.
- 334 2017;30(1):203-218. doi:10.5334/IRSP.90
- 335 25. Brazil | Commonwealth Fund. Accessed August 12, 2021.
- 336 https://www.commonwealthfund.org/international-health-policy-center/countries/brazil
- 337 26. Marine E, et al. Improving tuberculosis management in prisons: Impact of a rapid
- molecular point-of-care test. J Infect. 2021;82(2):235-239.
- doi:10.1016/J.JINF.2020.11.042
- Chang K, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance
 with Xpert MTB/RIF assay: A meta-analysis. *J Infect*. 2012;64(6):580-588.
- doi:10.1016/J.JINF.2012.02.012
- 28. Turaev L, et al. Universal Access to Xpert MTB/RIF Testing for Diagnosis of
- 344 Tuberculosis in Uzbekistan: How Well Are We Doing? Int J Environ Res Public Heal
- 345 2021, Vol 18, Page 2915. 2021;18(6):2915. doi:10.3390/IJERPH18062915
- 346 29. Ayala G, et al. Trends in tuberculosis notification and treatment outcomes in prisons: a
- 347 country-wide assessment in El Salvador from 2009-2014 Investigación original / Original
- 348 research Suggested citation Trends in tuberculosis notification and treatment outcomes in
- 349 prisons: a country-wide assessment in El. *Rev Panam Salud Publica*. 39(1):2016.
- 350 30. Moyenga I, et al. The impact of Xpert® MTB/RIF depends on service coordination:
- Experience in Burkina Faso. *Int J Tuberc Lung Dis.* 2015;19(3):285-287.
- doi:10.5588/IJTLD.14.0629
- 353
- 354
- 355

- **Table 1**. Multivariable regression for use of Xpert MTB/RIF and chest radiography with
- 357 municipality random effects. The odds ratios (OR), 95% confidence intervals (CI), and p-values
- are listed for each predictor, with significantly associated covariates in bold.

		Access to Xpert MTB/RIF			Access to Chest Radiography		
Predictors		OR	95% CI	р	OR	95% CI	р
Covariate							
	Population Density*	1.04	0.92 - 1.17	0.542	1.01	0.90 - 1.12	0.91
	Gini Coefficient**	0.98	0.72 - 1.35	0.913	1.50	1.12 - 2.03	0.00
	Incarcerated Population	1.76	1.49 - 2.08	<0.001	0.45	0.39 - 0.52	<0.0
	Size*						
	Average per Capita	1.40	0.88 - 2.22	0.156	3.33	2.10 - 5.30	<0.0
	Income*						
Tear							
	2015	Ref			Ref		
	2016	0.97	0.88 - 1.06	0.458	0.89	0.80 - 0.99	0.02
	2017	1.55	1.42 - 1.69	<0.001	0.97	0.88 - 1.07	0.56
	2018	2.23	2.03 - 2.44	<0.001	1.17	1.06 - 1.29	0.00
log-scale							

360 **rescaled by a factor of 10

361


- **Table 2.** Use of TB diagnostics among the incarcerated populations in selected municipalities.
- 363 We selected municipalities with incarcerated populations of at least 5000 and with at least 5 TB
- 364 incarcerated TB diagnoses between 2015 to 2018. Table columns indicate the incarcerated
- 365 population size and TB diagnoses for each municipality, as well as the percent of TB cases
- diagnosed with Xpert MTB/RIF or chest radiography, from 2015-2018.

Region	State	Municipality	Incarcerated Population Size,	Incarcerated TB Diagnoses, 2015-	% Diagnosed with Xpert	% Diagnosed with Chest	
			2018	2018	MTB/RIF	Radiography	
North	RO	Porto Velho	6475	265	55.1	37.7	
	AM	Manaus	7748	311	53.4	39.5	
	PA	Santa Izabel Do Pará	5439	339	1.5	40.4	
Northeast	MA	São Luís	5462	305	59.3	86.9	
	CE	Itaitinga	9670	569	38.0	24.4	
	PB	João Pessoa	5203	214	53.1	33.9	
	PE	Recife	6409	560	34.1	20.0	
	AL	Maceió	7619	107	67.3	25.2	
	BA	Salvador	5001	209	67.9	31.1	
Southeast	MG	Ribeirão Das Neves	9522	34	0.0	82.4	
		São Joaquim De Bicas	5278	17	5.9	47.1	
	ES	Vila Velha	7958	18	16.7	72.2	
	RJ	Rio De Janeiro	36243	3417	13.8	83.8	
	SP	Bauru	6601	347	65.1	16.4	
		Franco Da Rocha	9804	317	12.3	14.8	
		Guarulhos	7457	380	54.5	3.9	
		Hortolândia	6741	307	64.2	5.2	
		Lavínia	6291	297	63.0	2.0	
		Mirandópolis	5404	201	60.7	13.9	
		São Paulo	15252	914	65.0	21.0	
		Tremembé	6837	187	62.6	2.1	
South	RS	Charqueadas	5142	240	67.1	25.0	
		Porto Alegre	6204	614	57.8	92.0	
Central-	MS	Campo Grande	5572	435	37.9	49.0	

West	GO	Aparecida De	6440	268	87.3	6.0
		Goiânia				
	DF	Brasília	16359	138	60.9	51.4


367

- 369 Figure legends:
- 370
- 371 Figure 1: Venn diagram of TB diagnostic use. Percentage of newly diagnosed TB cases with
- diagnostic test results reported for 1) Xpert MTB/RIF, 2) Chest Radiography, 3) Smear, and 4)
- 373 Culture. Numbers in overlaps indicate individuals who received multiple diagnostic tests.



- 374
- 375 376

- **Figure 2:** Tuberculosis **diagnostic test use in Brazil.** Proportions of incarcerated (light blue)
- and non-incarcerated (dark blue) individuals diagnosed between 2015-2018 by A) Xpert
- 379 MTB/RIF, B) chest radiography, C) smear, and D) culture.
- 380





382

Figure 3: Spatial heterogeneity in the use of Xpert MTB/RIF and chest radiography among

384 the incarcerated population. A) Map of Brazilian states showing the percent of incarcerated

- individuals diagnosed with Xpert MTB/RIF between 2015 to 2018. Darker colors represent
- 386 greater diagnostic use. B) Map of Brazilian states showing the percent of incarcerated individuals
- diagnosed with chest radiography between 2015 to 2018. C) The variance in use of Xpert
- 388 MTB/RIF and chest radiography attributed to state (dark blue) and municipality (light blue)
- random effects as measured by the intraclass correlation coefficient (ICC).
- 390





396 Figure 4: Gaps use of Xpert MTB/RIF and chest radiography in the incarcerated

397 population. A) The proportion of incarcerated individuals in each municipality who were

- 398 diagnosed without Xpert MTB/RIF, colored by region. Longer bars suggest a greater gap in
- 399 diagnostic use. B) The proportion of incarcerated individuals in each municipality who were
- 400 diagnosed without chest radiography, colored by region. C) The 26 municipalities labeled within
- 401 a map of Brazil, colored by region.
- 402

